I started my PhD and early postdoctoral career at the Garvan Institute of Medical Research and the Children’s Cancer Institute, Sydney, as a cancer biologist focusing on the study of cell-intrinsic tumour-promoting signalling pathways, specifically a ubiquitin ligase involved in the DNA damage response and the role of ABC transporters in neuroblastoma. This led to a deep interest in the inflammatory tumour microenvironment and a post-doctoral position in Prof Wolfgang Weninger’s Immune Imaging Lab at the Centenary Institute. There, I used intravital microscopy to unveil the role of granzyme B in T cell extravasation and examined the dynamics of tumour-cytotoxic T cell interactions.
In 2015 I moved to the Bone Biology Division at the Garvan Institute. The Rogers lab seeks to understand the role of the mevalonate pathway in human health and disease, particularly in the context of inflammation and innate immunity. Our focus is on the molecular pharmacology of bisphosphonate drugs used to treat metabolic bone diseases, and the pathophysiology of the autoinflammatory disease Mevalonate Kinase Deficiency.
In the NewsAutoinflammatory Diseases Workshop: Learning is a two-way street - Sep 26, 2017
Proteins on the loose in a debilitating childhood disease - May 11, 2017
State Custodians Young Garvan Edgy Ideas awards night - Jun 21, 2016
1998 - BSc (Hons) (First Class) in Biology, Simon Bolivar University, Caracas - Venezuela
*Munoz, M.A., *Jurczyluk, J., Mehr, S., Chai, R.C., Arts, R.J.W., Sheu, A., McMahon, C., Center, J.R., Singh-Grewal, D., Chaitow, J., Campbell, D.E., Quinn, J.M.W., Alexandrov, K., Tnimov, Z., Tangye, S.G., Simon, A., Phan, T.G. & Rogers, M.J. Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency. J Allergy Clin Immunol 2017 (in press). *Equal author contribution
*Jurczyluk, J., *Munoz, M., Skinner, O.P., Chai, R.C., Ali, N., Palendira, U., Quinn, J.M.W., Preston, A., Tangye, S.G., Brown, A.J., Argent, E., Ziegler, J.B., Mehr, S. & Rogers, M.J. Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases. Immunology & Cell Biology 2016; 94:994-999. *Equal author contribution
Ali, N., Jurczyluk, J., Shay, G., Tnimov, Z., Alexandrov, K., Munoz, M.A., Skinner, O.P., Pavlos, N.J. & Rogers, M.J. A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton. Small GTPases 2015; 6:202-211.
*Prakash, M. D., *Munoz, M. A., Jain, R., Tong, P. L., Koskinen, A., Regner, M., Kleifeld, O., Ho, B., Olson, M., Turner, S. J., Mrass, P., Weninger, W. and Bird, P. I. (2014). "Granzyme B promotes cytotoxic lymphocyte transmigration via basement membrane remodeling." Immunity 41(6): 960-972.(Prakash et al. 2014) *Equal author contribution
Munoz, M. A., Biro, M. and Weninger, W. (2014). "T cell migration in intact lymph nodes in vivo." Current opinion in cell biology 30: 17-24.
*Biro, M., *M. A. Munoz and W. Weninger (2014). "Targeting Rho-GTPases in immune cell migration and inflammation." Br J Pharmacol. *Equal author contribution
Cheung, L., C. L. Flemming, F. Watt, N. Masada, D. M. Yu, T. Huynh, G. Conseil, A. Tivnan, A. Polinsky, A. V. Gudkov, M. A. Munoz, A. Vishvanath, D. M. Cooper, M. J. Henderson, S. P. Cole, J. I. Fletcher, M. Haber and M. D. Norris (2014). "High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)." Biochem Pharmacol 91(1): 97-108.
Haass, N. K., K. A. Beaumont, D. S. Hill, A. Anfosso, P. Mrass, M. A. Munoz, I. Kinjyo and W. Weninger (2014). "Real-time cell cycle imaging during melanoma growth, invasion, and drug response." Pigment Cell Melanoma Res 27(5): 764-776.
Beaumont, K. A., M. A. Munoz and W. Weninger (2013). "Mesenchymal cells hold the key to immune cell recruitment to and migration within melanoma." J Invest Dermatol 133(9): 2138-2140.
Dr Marcia MunozEmail: Click here to Email